Zai Lab Strengthens Oncology Pipeline with US$ 338 M Mirati Alliance in Greater China
By Swati Sharan & Michelle Liu
Pharma Deals Review: Vol 2021 Issue 6 (Table of Contents)
Published: 29 Jun-2021
DOI: 10.3833/pdr.v2021.i6.2617 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a bid to broaden its lung cancer franchise, Zai Lab has entered into a collaboration and license agreement with Mirati Therapeutics to develop and commercialise adagrasib for the treatment of cancer associated with KRAS G12C mutationin Greater China...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS